<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=4423596&amp;fmt=gif">
Discover AGCellerate™ for LVV - a faster option to get your GMP-ready lentiviral vector product   Learn about AGCellerate

QA Mammalian build vs buy when to outsource download graphic


Should you Outsource your  Protein Biologics Bioprocessing?


This Q&A details important answers to questions biopharma companies must consider when deciding to develop or expand in-house production and manufacturing. We also explore the benefits of tapping into a biopharmaceutical CDMO's diverse global network of scientific experience and resources to accelerate development and manufacturing, while also reducing risk and, often, costs.

Key Takeaways

  • Factors that limit scale-up for mammalian cell cultures

  • key considerations for in-house vs outsourcing

  • CDMO supply chain support/raw material acquisition

  • Making the scale-up process more predictable